Jeffrey D. Abbey Sells 114,702 Shares of Argos Therapeutics Inc (ARGS) Stock

Argos Therapeutics Inc (NASDAQ:ARGS) CEO Jeffrey D. Abbey sold 114,702 shares of Argos Therapeutics stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $0.16, for a total transaction of $18,352.32. Following the completion of the sale, the chief executive officer now owns 635,033 shares in the company, valued at $101,605.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Argos Therapeutics Inc (ARGS) traded down $0.01 during midday trading on Friday, hitting $0.16. 5,873,811 shares of the stock were exchanged, compared to its average volume of 3,220,000. The company has a quick ratio of 2.29, a current ratio of 2.29 and a debt-to-equity ratio of -1.46. Argos Therapeutics Inc has a 12 month low of $0.13 and a 12 month high of $5.68. The firm has a market capitalization of $14.02, a P/E ratio of -0.14 and a beta of 1.38.

A hedge fund recently bought a new stake in Argos Therapeutics stock. Wasatch Advisors Inc. acquired a new stake in Argos Therapeutics Inc (NASDAQ:ARGS) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 665,831 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Wasatch Advisors Inc. owned about 1.21% of Argos Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 18.35% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Equities Focus and is the sole property of of Equities Focus. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at

About Argos Therapeutics

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply